UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

Filed	I by a party other than the Registrant \square				
Filed	d by the Registrant ☑				
CHE	CHECK THE APPROPRIATE BOX:				
	Preliminary Proxy Statement				
	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))				
	Definitive Proxy Statement				
V	Definitive Additional Materials				
	Soliciting Material under Sec.240.14a-12				
	RenaissanceRe ⁻				
	RenaissanceRe Holdings Ltd. (Name of Registrant as Specified In Its Charter)				
	(Name of Person(s) Filing Proxy Statement, if other than the Registrant)				
PAY	MENT OF FILING FEE (CHECK ALL BOXES THAT APPLY):				
7	No fee required				
	Fee paid previously with preliminary materials				
	Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11				





Board of Directors Voting Recommendations

Our Board seeks your support at our 2024 Annual General Meeting of Shareholders to be held on May 13, 2024

Election of Three Class II Director Nominees

We recommend FOR our highly qualified nominees, who have extensive experience, education and diverse personal skills that contribute to their effectiveness as Board members

Advisory Vote on the Compensation of our Named Executive Officers

- We recommend FOR our executive compensation program which is designed to support RenaissanceRe's long-term strategy and risk management, align the interests of our shareholders and executives, and encourage operational and financial consistency over market cycles and through earnings volatility inherent to our industry. Performance recognition awards granted in support of our acquisition of Validus have rigorous performance goals, are distinct from our annual program and serve the purpose of:
 - ✓ Incentivizing future outperformance and driving shareholder value
 - ✓ Supporting leadership continuity and retention amidst the transformative Validus acquisition
 - ✓ Recognizing the significant additional managerial and oversight responsibilities necessary from our CEO to maximize the value of the Validus acquisition

3

Approval of the Appointment of PricewaterhouseCoopers Ltd. As Auditor

> We recommend FOR the approval of the appointment of PricewaterhouseCoopers Ltd., who has served as our auditor since 2022



Strategic, Operational and Financial Highlights

We delivered strong strategic, operational and financial returns in 2023, enhanced by the acquisition of Validus, which positions us to create enduring shareholder value moving forward

2023 HIGHLIGHTS

November 2023 Validus Acquisition

- Gained access to an attractive portfolio that complements our existing business mix
- Immediately accretive to book value per share and return on average common equity
- Increased contributions from diversified earnings streams across Three Drivers of Profit
- Advances our strategy to be a leading Global Property & Casualty (P&C) Reinsurer
- Capital fully deployed on day 1, and Validus underwriting portfolio integrated into our risk management system soon afterwards, diminishing execution risk

Strong Operational Performance


- Net Income Available to Common Shareholders of \$2.5 billion and Operating Income Available to Common Shareholders of \$1.8 billion(1)
- Return on Average Common Equity of 40.5% and Operating Return on Average Common Equity of 29.3%(1)
- Change in Book Value per Common Share plus Change in Accumulated Dividends of 59.3%

Underwriting Accomplishments

- Underwriting Income of \$1.6 billion
- Gross Premiums Written of \$8.9 billion
- Combined Ratio of 77.9%

2023 results demonstrate strong performance over time, through challenging market conditions

- Since Mr. O'Donnell was named CEO in 2013, we have transformed into a global leader in the P&C reinsurance space
- Mr. O'Donnell spearheaded three successful acquisitions over his tenure that are driving RenaissanceRe's long-term strategy into its next stage of growth



⁽¹⁾ Operating income available to common shareholders and operating return on average common equity are non-GAAP financial measures. A reconciliation of non-GAAP financial measures is included in Appendix A below

(2) Total shareholder return is dividend adjusted and measured from January 2, 2013 through December 29, 2023. Source: S&P Capital IQ database.

RenaissanceRe.com | pg. 3

RenaissanceRe>

Board of Directors

Our Board brings a wide range of professional experience and diverse perspectives which contribute to their active oversight of strategy to serve the long-term interests of shareholders

Director Nominees



Brian G. J. Gray Former Group Chief Underwriting Officer, Swiss Reinsurance Committees: I*, T, O Director Since 2013



Duncan P. Hennes Co-Founder, Managing Member, Atrevida Partners Committees: I Director Since 2017



Kevin J. O'Donnell President & CEO, RenaissanceRe Committees: T*, O* Director Since 2013

Continuing Directors



Henry Klehm III Jones Day Committees: G* Director Since 2006



David C. Bushnell Retired Chief Administrative Officer, Citigroup Committees: G Director Since 2008



Cynthia Trudell Former CHRO, PepsiCo Committees: G Director Since 2019





Shyam Gidumal Former President & COO, WeWork Committees: A Director Since 2022



Valerie Rahmani Former CEO, Damballa Committees: A Director Since: 2017



Audit (A), Governance & Human Capital (G), Investment & Risk Management (I), Offerings (O), Transaction (T); Chair (*)


Committed to Diversity

Rigorous director evaluation and selection criteria, which encourage diversity and refreshment



new directors in the last 5 years

Committed to seek new Board candidates who embody all aspects of diversity, including racial, ethnic and gender diversity





James L. Gibbons Independent Chair. RenaissanceRe Committees: T, O Director Since 2008



Torsten Jeworrek Former Member of Board of Management Munich Reinsurance Committees: I, T, O Director Since 2023

Relevant Skills and Experience for RenaissanceRe

- Executive Management (Re)insurance Operations
 - Sustainability
 - International
 - Technology / Cybersecurity
- ✓ Financial & Audit
- ✓ Data Analytics / Digital
- ✓ Actuarial

- Underwriting
- ✓ Risk / Compliance / Regulation
- ✓ Public Company CEO

RenaissanceRe.com | pg. 4

- Strategic Transactions
- Investments / Asset Management
- Talent / Human Capital



2023 Annual Compensation Program Overview

The Corporate Governance and Human Capital Management Committee has designed a program with rigorous performance goals to align pay with performance

rank compared to peers (25%)

			Description	Performance Period / Metrics
Short-Term		Salary	Fixed component of compensation	 Reflects expertise and scope of responsibilities in a competitive market for executive talent
	At -Risk Pay	Annual Incentive Bonus	Annual, at-risk cash incentive program designed to promote achievement of financial metrics and strategic accomplishments against pre-defined targets that support long-term growth and operational efficiencies	One-year performance period Metrics (weighting): Combined ratio rank relative to peers (16.7%) Ratio of operating return on average common equity to peer median (33.3%) Ratio of actual gross premiums written to budget (16.7%) Board-approved strategic accomplishments (33.3%)
Long-Term		Long-Term Incentive Awards (At-risk, long-	Time-Vested Restricted Shares Subject to service-based vesting Comprise 50% of annual long-term incentive awards for all Named Executive Officers	 Four-year vesting period (equal annual installments)
Long-		term, equity- based compensation to encourage multi-year performance and retention)	Performance Shares Subject to both performance- and service-based vesting Comprise 50% of annual long-term incentive awards for all Named Executive Officers	Three-year performance / vesting period Metrics (weighting): Average change in book value per common share plus change in accumulated dividends (75%) Average underwriting expense ratio



⁽¹⁾ Due to rounding, percentages may not total precisely.



2023 Performance Recognition Awards

Following the successful acquisition of Validus in November 2023, the Corporate Governance and Human Capital Management Committee granted a performance recognition award to Mr. O'Donnell

Rationale and Considerations for CEO Award

- · Although the Governance and Human Capital Committee has not historically utilized one-time awards, it considered the transformational acquisition of Validus an extraordinary circumstance for the Company. The Committee does not have plans to grant any additional one-time
- The award's final structure and terms were the culmination of a thoughtful and robust deliberation by the Committee to create an incentive that is in the best interests of shareholders, appropriately recognizes our CEO for his tremendous efforts in securing the acquisition for the Company and retains him during this pivotal period. As a result, this award:
 - ✓ Incentivizes significant outperformance and drives the Company's strategic direction and value creation over the long-term
 - Supports leadership continuity through the critical integration of Validus, marking a pivotal point in the Company's long-term growth strategy
 - Recognizes the significant additional managerial and oversight responsibilities necessary from our CEO to maximize the value of the Validus acquisition

CEO Award Structure

• The length and structure of the award was thoughtfully designed to be distinct from our annual program and drive strong outcomes for shareholders

Performance Share Award (60% of award)

- o Four-year performance / vesting period
 - Longer than annual performance-based awards and aligned with Validus integration period
- o Metric of average change in tangible book value per share plus change in accumulated dividends
 - Incentivizes organic growth, reflecting success in integrating Validus without being impacted by intangible assets of acquisition
- o Higher thresholds and targets than our annual performance share awards to make them more challenging to achieve
 - ✓ Rigor is further enhanced because of inherent volatility of reinsurance industry

Restricted Share Award (40% of award)

- o Five-year performance / vesting period
 - Extended to support retention during this critical time
- o Management-related performance goals must be achieved by Mr. O'Donnell to vest, including his role in:
 - ✓ Maximizing potential value that Validus acquisition brings to shareholders through integration
 - ✓ Leading as we bring together two businesses and accelerate our long-term strategy, developing talent, including new Validus employees, and long-term succession planning



Cautionary Statement on Forward Looking Statements

Any forward-looking statements made in this presentation reflect the current views of RenaissanceRe Holdings Ltd. ("RenaissanceRe" or the "Company") with respect to future events and financial performance and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company may also make forward-looking statements with respect to its business and industry, such as those relating to its strategy and management objectives, plans and expectations regarding its response and ability to adapt to changing economic conditions, market standing and product volumes, estimates of net negative impact and insured losses from loss events, and the Validus Acquisition and its impact on the Company's business, among other things. These statements are subject to numerous factors that could cause actual results to differ materially from those addressed by such forward-looking statements, including the following: the Company's exposure to natural and non-natural catastrophic events and circumstances and the variance it may cause in the Company's financial results; the effect of climate change on the Company's business, including the trend towards increasingly frequent and severe climate events; the effectiveness of the Company's claims and claim expense reserving process; the effect of emerging claims and coverage issues; the performance of the Company's investment portfolio and financial market volatility; the effects of inflation; the ability of the Company's ceding companies and delegated authority counterparties to accurately assess the risks they underwrite; the Company's ability to maintain its financial strength ratings; the Company's reliance on a small number of brokers; the highly competitive nature of the Company's industry; the historically cyclical nature of the (re)insurance industries; collection on claimed retrocessional coverage, and new retrocessional reinsurance being available on acceptable terms or at all; the Company's ability to attract and retain key executives and employees; the Company's ability to successfully implement its business strategies and initiatives; difficulties in integrating Validus; the Company's exposure to credit loss from counterparties; the Company's need to make many estimates and judgments in the preparation of its financial statements; the Company's exposure to risks associated with its management of capital on behalf of investors in joint ventures or other entities it manages; changes to the accounting rules and regulatory systems applicable to the Company's business, including changes in Bermuda and U.S. laws and regulations; the effect of current or future macroeconomic or geopolitical events or trends, including the ongoing conflicts between Russia and Ukraine, and Israel and Hamas; other political, regulatory or industry initiatives adversely impacting the Company; the Company's ability to comply with covenants in its debt agreements; the effect of adverse economic factors, including changes in prevailing interest rates; the impact of cybersecurity risks, including technology breaches or failure; a contention by the U.S. Internal Revenue Service that any of the Company's Bermuda subsidiaries are subject to taxation in the U.S.; the effects of new or possible future tax reform legislation and regulations in the jurisdictions in which the Company operates, including recent changes in Bermuda tax law; the Company's ability to determine any impairments taken on its investments; the Company's ability to raise capital on acceptable terms, including through debt instruments, the capital markets, and third party investments in the Company's joint ventures and managed fund partners; the Company's ability to comply with applicable sanctions and foreign corrupt practices laws; the Company's dependence on capital distributions from its subsidiaries; and other factors affecting future results disclosed in RenaissanceRe's filings with the SEC, including its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to revise or update forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

RenaissanceRe>

Appendix A



Appendix A: Comments on Non-GAAP Financial Measures

We have included certain non-GAAP financial measures within the meaning of Regulation G in this presentation. We have provided certain of these financial measures in previous investor communications and our management believes that such measures are important to investors and other interested persons, and that investors and such other persons benefit from having a consistent basis for comparison between periods and for comparison with other companies within or outside the industry. These measures may not, however, be comparable to similarly titled measures used by companies within or outside of the insurance industry. Investors are cautioned not to place undue reliance on these non-GAAP measures in assessing our overall financial performance.

Operating Income (Loss) Available (Attributable) to RenaissanceRe Common Shareholders and Operating Return on Average Common Equity

We use "operating income (loss) available (attributable) to RenaissanceRe common shareholders" as a measure to evaluate the underlying fundamentals of its operations and believe it to be a useful measure of our corporate performance. "Operating income (loss) available (attributable) to RenaissanceRe common shareholders" as used herein differs from "net income (loss) available (attributable) to RenaissanceRe common shareholders," which we believe is the most directly comparable GAAP measure, by the exclusion of (1) net realized and unrealized gains and losses on investments, excluding other investments - catastrophe bonds, (2) net foreign exchange gains and losses, (3) corporate expenses associated with acquisitions and dispositions, (4) acquisition related purchase accounting adjustments, (5) the Bermuda net deferred tax asset, (6) the income tax expense or benefit associated with these adjustments, and (7) the portion of these adjustments attributable to the Company's redeemable noncontrolling interests. We updated our calculation of "operating income (loss) available (attributable) to RenaissanceRe common shareholders" to exclude "acquisition related purchase accounting adjustments" because we believe that excluding the impact of acquisition related accounting adjustments provides more comparability and a more accurate measure of our results of operations. We also use "operating income (loss) available (attributable) to RenaissanceRe common shareholders" to calculate "operating return on average common equity."

Our management believes that "operating income (loss) available (attributable) to RenaissanceRe common shareholders" and "operating return on average common equity" are useful to management and investors because they provide for better comparability and more accurately measure our results of operations and remove variability.

The following table is a reconciliation of: (1) net income (loss) available (attributable) to RenaissanceRe common shareholders to "operating income (loss) available (attributable) to RenaissanceRe common shareholders"; and (2) return on average common equity to "operating return on average common equity." Comparative information for the prior periods presented have been updated to conform to the current methodology and presentation.



Appendix A: Comments on Non-GAAP Financial Measures

	Year Ended December 31,	
(in thousands of U.S. dollars, except per share amounts and percentages)	2023	2022
Net income (loss) available (attributable) to RenaissanceRe common shareholders	\$2,525,757	\$(1,096,578)
Adjustment for:		
Net realized and unrealized losses (gains) on investments, excluding other investments - catastrophe bonds	(312,625)	1,670,150
Net foreign exchange losses (gains)	41,479	56,909
Corporate expenses associated with acquisitions and dispositions	76,380	_
Acquisition related purchase accounting adjustments ⁽¹⁾	64,866	7,235
Bermuda net deferred tax asset ⁽²⁾	(593,765)	_
Income tax expense (benefit) ⁽³⁾	3,289	(83,149)
Net income (loss) attributable to redeemable noncontrolling interests ⁽⁴⁾	19,529	(231,776)
Operating income (loss) available (attributable) to RenaissanceRe common shareholders	\$1,824,910	\$322,791
Return on average common equity	40.5%	(22.0)%
Adjustment for:		
Net realized and unrealized losses (gains) on investments, excluding other investments - catastrophe bonds	(5.0)%	33.5 %
Net foreign exchange losses (gains)	0.7 %	1.1 %
Corporate expenses associated with acquisitions and dispositions	1.2%	_
Acquisition related purchase accounting adjustments ⁽¹⁾	1.0%	0.1%
Bermuda net deferred tax asset ⁽²⁾	(9.5)%	_
Income tax expense (benefit) ⁽³⁾	0.1%	(1.7)%
Net income (loss) attributable to redeemable noncontrolling interests ⁽⁴⁾	0.3%	(4.6)%
Operating return on average common equity - annualized	29.3 %	6.4 %



Appendix A: Comments on Non-GAAP Financial Measures

- Represents the purchase accounting adjustments related to the amortization of acquisition related intangible assets, amortization (accretion) of VOBA and acquisition costs, and the fair value adjustments to the net reserves for claims and claim expenses for the years ended December 31, 2023 and 2022, respectively, for the acquisitions of Validus \$48.8 million (2022 - \$Nil); and TMR and Platinum \$16.1 million (2022 - \$7.2 million).
- Represents the net deferred tax benefit resulting from the recognition of deferred tax assets net of deferred tax liabilities in connection with a 15% Bermuda corporate income tax rate, pursuant to the Corporate Income Tax Act 2023, enacted on December 27, 2023.
- Represents the income tax (expense) benefit associated with the adjustments to net income (loss) available (attributable) to RenaissanceRe common shareholders. The income tax impact is estimated by applying the statutory rates of applicable jurisdictions, after consideration of other relevant factors.
- Represents the portion of the adjustments above that are attributable to the Company's redeemable noncontrolling interests, including the income tax impact of those adjustments.